Ruxolitinib: The First FDA Approved Therapy for the Treatment of Myelofibrosis Full Text
Clinical Cancer Research,  Clinical Article

Mascarenhas J et al. – Ruxolitinib offers a well–tolerated oral therapeutic option for patients with myelofibrosis with symptomatic splenomegaly and debilitating disease–related symptoms, but it does not seem to be effective at eliminating the underlying hematological malignancy.

Please login or register to follow this author.
► Click here to access Full Text, PubMed, Publisher and related articles...
<< Previous Article | Next Article >>

    Currently, there are no available articles.

Your Unread Messages in Internal Medicine

See All >> Messages include industry-sponsored communications and special communications from MDLinx

Most Popular Internal Medicine Articles

Indexed Journals in Internal Medicine: New England Journal of Medicine, The Lancet, Archives of Internal Medicinemore